Table 1.
The therapeutic effects of some selected Saporin-based immunotoxins in preclinical in vivo models of human malignancies. ALL, acute lymphoblastic leukemia; B-NHL, B-cell non-Hodgkin’s lymphoma; T-ALL, T-cell acute lymphoblastic leukemia; ALCL, anaplastic large cell lymphoma.
| IT/TT | Target Antigen(s) | Preclinical Model | Comment | Reference |
|---|---|---|---|---|
| BU12-Saporin | CD19 | SCID Mouse-NALM-6 (pre-B ALL) | BU12-Saporin treatment gave a significant prolongation in survival | [33] |
| Ber-H2/Saporin | CD30 | SCID mouse-JB6 (ALCL) | Significant inhibition of solid tumor growth in Ber-H2-Saporin treated animals | [40] |
| HB2-Saporin + OKT10-Saporin combination | CD7 and CD38 | SCID-HSB-2 T-ALL | Combination of two ITx significantly better therapeutically | [43] |
| BU12-Saporin + OKT10-Saporin + 4KB128-Saporin | CD19, CD22 and CD38 | SCID mouse-Ramos (B-NHL) | Individual ITx curative of only a proportion of animals. Combination of all three ITs curative of all | [44] |
| BU12-Saporin + rituximab | CD19 and CD20 | SCID mouse-Ramos (B-NHL) | Combination of IT + rituximab antibody significantly better than individual monotherapies | [45] |
| EV20-SAP | HER3 | SCID Mouse-melanoma (cells) | EV20-Saporin treatment significantly reduced pulmonary metastases in a melanoma xenograft model | [46] |